No association of the MTHFR gene A1298C polymorphism with the risk of prostate cancer: A meta-analysis

Experimental and Therapeutic Medicine

Volumn 3, Issue 3, 2012, Pages 493-498

  Li, Dawei ^a,b   Tian, Tian ^c   Guo, Chunhui ^c   Ren, Juchao ^a,b   Yan, Lei ^a   Liu, Hainan ^a   Xu, Zhonghua ^a  

^a SHANDONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Tuberculosis Hospital of Binzhou City   (China)

Author keywords

10 methylenetetrahydrofolate reductase; 5; Meta analysis; Polymorphism; Prostate cancer

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; ETHNICITY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; PATHOGENESIS; PROSTATE CANCER; SENSITIVITY ANALYSIS;

EID: 84862957331     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.445     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Bray F, Sankila R, Ferlay J and Parkin DM: Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38: 99-166, 2002.
3. Hsing AW and Chokkalingam AP: Prostate cancer epidemiology. Front Biosci 11: 1388-1413, 2006.
4. Jung KW, Won YJk S, et al: Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 24: 995-1003, 2009.
5. Mason JB and Levesque T: Folate: effects on carcinogenesis and the potential for cancer chemoprevention. Oncology 10: 1727-1736, 1742-1724, 1996.
6. Kim YI: Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem 10: 66-88, 1999.
7. Goyette P, Sumner JS, Milos R, et al: Human methylenetetrahy drofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 7: 195-200, 1994.
8. Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahy-drofolate reductase. Nat Genet 10: 111-113, 1995.
9. Dobosy JR, Roberts JL, Fu VX and Jarrard DF: The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 177: 822-831, 2007.
10. Murphy TMry AS and Lawler M: The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr Relat Cancer 15: 11-25, 2008.
11. Goyette P, Pai A, Milos R, et al: Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm Genome 9: 652-656, 1998.
12. Kurzawski M, Dziewanowski K, Kedzierska K, Wajda A, Lapczuk J and Droździk M: Association of transcription factor7-like 2 (TCF7L2) gene polymorphism with posttrans plant diabetes mellitus in kidney transplant patients medicated with tacrolimus. Pharmacol Rep 63: 826-833, 2011.
13. Leu JD, Wang CY, Tsai HY, Lin IF, Chen RC and Lee YJ: Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer. Oncol Rep 25: 1755-1763, 2011.
14. Kim JWk HM, Choi YK, Chong SY, Oh D and Kim NK: Polymorphisms in genes involved in folate metabolism and plasma DNA methylation in colorectal cancer patients. Oncol Rep 25: 167-172, 2011.
15. Fung MM, Salem RM, Lipkowitz MS, et al: Methylene tetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the 0041frican-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC). Nephrol Dial Transplant: May, 2011 (E-pub ahead of print).
16. Dayakar S, Goud KI, Reddy TP, Rao SP, Sesikeran SB and Sadhnani M: Sequence variation of the methylene tetrahydrofolate reductase gene (677C>T and 1298 A>C) and traditional risk factors in a South Indian population. Genet Test Mol Biomarkers: July, 2011 (E-pub ahead of print).
17. Siemianowicz K, Gminski J, Garczorz W, et al: Methylene tetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and non-small cell lung cancer. Oncol Rep 10: 1341-1344, 2003.
18. Shen H, Newmann AS, Hu Z, et al: Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. Oncol Rep 13: 355-360, 2005.
19. Cicek MS, Nock NL, Li L, Conti DV, Casey G and Witte JS: Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 13: 1331-1336, 2004.
20. Singal R, Ferdinand L, Das PM, Reis IM and Schlesselman JJ: Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Int J Oncol 25: 1465-1471, 2004.
21. Van Guelpen BR, Wirén SM, Bergh AR, Hallmans G, StattinPE and Hultdin J: Polymorphisms of methylenetetrahydrofolate reductase and the risk of prostate cancer: a nested case-control study. Eur J Cancer Prev 15: 46-50, 2006.
22. Marchal C, Redondo M, Reyes-Engel A, et al: Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer. Eur J Surg Oncol 34: 805-810, 2008.
23. Stevens VL, Rodriguez C, Sun J, Talbot JT, Thun MJ and CalleEE: No association of single nucleotide polymorphisms in one-carbon metabolism genes with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 17: 3612-3614, 2008.
24. Muslumanoglu MH, Tepeli E, Demir S, et al: The analysis of the relationship between A1298C and C677T polymorphisms of the MTHFR gene with prostate cancer in Eskisehir population. Genet Test Mol Biomarkers 13: 641-645, 2009.
25. Cai D, Ning L, Pan C, et al: Association of polymorphisms in folate metabolic genes and prostate cancer risk: a case-control study in a Chinese population. J Genet 89: 263-267, 2010.
26. Safarinejad MR, Shafiei N and Safarinejad S: Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: a case-control study. Prostate 70: 1645-1657, 2010.
27. Wu HC, Chang CH, Tsai RY, et al: Significant association of methylenetetrahydrofolate reductase single nucleotide polymor-phisms with prostate cancer susceptibility in Taiwan. Anticancer Res 30: 3573-3577, 2010.
28. Weisberg IS, Jacques PF, Selhub J, et al: The 1298A-->C poly morphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis156: 409-415, 2001.
29. van der Put NM, Gabreëls F, Stevens EM, et al: A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62: 1044-1051, 1998.
30. Bai JL, Zheng MH, Xia X, Ter-Minassian M, Chen YP and ChenF: MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: a meta-analysis of 3511 cases and 2762 controls. Eur J Cancer 45: 1443-1449, 2009.
31. Collin SM, Metcalfe C, Zuccolo L, et al: Association of folate pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 18: 2528-2539, 2009.
32. Dong X, Wu J, Liang P, Li J, Yuan L and Liu X: Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysis. Arch Med Res41: 125-133, 2010.
33. Qiu LX, Zhang J, Li WH, et al: Lack of association between met{stroke}hylenetetrahydrofolate reductase gene A1298C polymor-phism and breast cancer susceptibility. Mol Biol Rep 38: 2295-2299, 2011.
34. Wei B, Xu Z, Ruan J, et al: MTHFR 677C>T and 1298A>C polymorphisms and male infertility risk: a meta-analysis. Mol Biol Rep: June, 2011 (E-pub ahead of print).
35. Hirschhorn JN, Lohmueller K, Byrne E and Hirschhorn K: A comprehensive review of genetic association studies. Genet Med4: 45-61, 2002.
36. Lievers KJ, Boers GH, Verhoef P, et al: A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med (Berl) 79: 522-528, 2001.